Related references
Note: Only part of the references are listed.Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study
T. M. E. Davis et al.
DIABETOLOGIA (2011)
PPARγ agonists inhibit angiogenesis by suppressing PKCα- and CREB-mediated COX-2 expression in the human endothelium
Egeria Scoditti et al.
CARDIOVASCULAR RESEARCH (2010)
Systematic approach for the management of chronic kidney disease: moving beyond chronic kidney disease classification
Rafael Burgos-Calderon et al.
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2010)
Effects of Long-Term Fenofibrate Treatment on Markers of Renal Function in Type 2 Diabetes - The FIELD Helsinki substudy
Carol Forsblom et al.
DIABETES CARE (2010)
Association between cardiac autonomic neuropathy and hypertension and its potential influence on diabetic complications
F. Ayad et al.
DIABETIC MEDICINE (2010)
Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
David C. Burgess et al.
EUROPEAN HEART JOURNAL (2010)
Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial
Faramarz Ismail-Beigi et al.
LANCET (2010)
Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes.
Emily Y. Chew et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus.
Lukasz Januszkiewicz
KARDIOLOGIA POLSKA (2010)
Impact of metabolic syndrome and its severity on microvascular complications in type 2 diabetes
Michel P. Hermans et al.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2010)
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
Henry N. Ginsberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Proteinuria as a Surrogate Outcome in CKD: Report of a Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration
Andrew S. Levey et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2009)
Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
Russell Scott et al.
DIABETES CARE (2009)
Combined Effects of Routine Blood Pressure Lowering and Intensive Glucose Control on Macrovascular and Microvascular Outcomes in Patients With Type 2 Diabetes New results from the ADVANCE trial
Sophia Zoungas et al.
DIABETES CARE (2009)
Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial
Kushwin Rajamani et al.
LANCET (2009)
Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
William Duckworth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Fenofibrate and diabetic retinopathy
Ning Cheung et al.
LANCET (2008)
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
Anushka Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Effects of intensive glucose lowering in type 2 diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Role of Peroxisome Proliferator-Activated Receptor Alpha in the Control of Cyclooxygenase 2 and Vascular Endothelial Growth Factor: Involvement in Tumor Growth
Raquel Grau et al.
PPAR RESEARCH (2008)
Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial
A. C. Keech et al.
LANCET (2007)
Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway
Jaetaek Kim et al.
EXPERIMENTAL EYE RESEARCH (2007)
Microvascular endothelial function in subjects with Type 2 diabetes and the effect of lipid-lowering therapy
PG Fegan et al.
DIABETIC MEDICINE (2005)
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):: randomised controlled trial
A Keech et al.
LANCET (2005)
Effect of Fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes Mellitus
J Genest et al.
AMERICAN JOURNAL OF CARDIOLOGY (2004)
PPARα activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1-dependent DNA binding and transactivation
M Meissner et al.
CIRCULATION RESEARCH (2004)
Prevalence, care, and outcomes for patients with diet-controlled diabetes in general practice: cross sectional survey
J Hippisley-Cox et al.
LANCET (2004)
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
P Gaede et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Relation of gemfibrozil treatment and lipid levels with major coronary events - VA-HIT: A randomized controlled trial
SJ Robins et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
IM Stratton et al.
BMJ-BRITISH MEDICAL JOURNAL (2000)
Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease - The bezafibrate infarction prevention (BIP) study
Z Schlesinger et al.
CIRCULATION (2000)
Share Paper
